Taro's Keveyis 50 mg Tablets Available for Treatment of Primary Hyperkalemic, Hypokalemic Periodic Paralysis

By: via Benzinga
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that Keveyis™ (dichlorphenamide) 50 mg Tablets, the first ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.